Kymera Therapeutics KYMR
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 3rd percentile, 5-year average -9.6x
Near the top of its 5-year range · 97th percentile, 5-year average 4.0x
#4682 of 5336 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 86th percentile, 5-year average 54.6x
#4965 of 5159 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 6.75 | – | 3.98 | 97% (pricier than usual) | #4682 of 5336 (1 = cheapest) |
| PE | -35.05 | -19.56 | -9.55 | 3% (cheaper than usual) | – |
| PS | 106.53 | 415.22 | 54.59 | 86% (pricier than usual) | #4965 of 5159 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on KYMR.
Sign in to join the discussion.